Benchmark Downgrades Neogenomics (NEO) to Hold, 'A Company In Transition'
Tweet Send to a Friend
Benchmark analyst Bruce Jackson downgraded Neogenomics (NASDAQ: NEO) from Buy to Hold.The analyst comments "NeoGenomics has a new CEO and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
